



8 August 2017

ASX ANNOUNCEMENT

First patient enrolled in SOZO™ CHF Trial at Scripps Health

Brisbane, Australia and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, is pleased to announce the first patient has been enrolled in the initial chronic heart failure (CHF) trial using SOZO™, at Scripps Health.

This initial study will monitor up to 30 patients with chronic heart failure in a clinical setting for 30 days, and is expected to be completed in CY 2017. The real-world data generated will be used to form the basis for the design of the larger scale trial expected to be initiated by late CY 2017.

"We are excited to see patient enrollment in the first SOZO™ trial for heart failure has begun. The trial, together with the other planned initial trials, will form the foundation of our marketing of SOZO™ in the heart failure indication in the US and other select international markets," said Richard Carreon, Managing Director and CEO of ImpediMed.

This initial trial is designed to use SOZO™ to measure fluid levels in Class III CHF patients. If successful, SOZO™ may provide an early warning system for cardiac decompensation with the potential to optimise patient care and significantly reduce hospital readmissions.

The Company obtained CE Mark for SOZO™ in June 2017 and plans to initiate the European launch of SOZO™ in key commercial sites in CY 2017.

CHF is among the most expensive diseases for Medicare in the US. An estimated 6.5 million people in the US suffer from heart failure, with more than 850,000 new patients diagnosed each year. Heart failure currently costs the US an estimated \$31 billion per year, and is estimated to increase to \$70 billion by 2030. 80% of the current costs are spent on hospitalisations.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

For personal use only

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex® device. In addition, ImpediMed produces a family of CE Marked medical devices, including SOZO™, sold in select markets globally.

For more information, visit www.impedimed.com.